公开(公告)号：US20210009597A1

公开(公告)日：2021-01-14

申请号：US16958721

申请日：2018-12-26

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： Shih-Chieh YEN ,  Chu-Bin LIAO ,  Hui-Chen WANG ,  Po-Ting CHEN ,  Yu-Chih PAN ,  Tsung-Hui LI ,  Bo-Rong CHEN ,  Shian-Yi CHIOU

IPC: C07D487/04 ,  A61P35/00

Abstract: Disclosed are compounds of formula (I) below and tautomers, stereoisomers, isotopologues, or pharmaceutically acceptable salts thereof: in which each of variables R1, ring A, L, W, V, and G is defined herein. Also disclosed are a method for treating disease or disorder mediated by Tyro3, Axl, and/or Mer kinase with a compound of formula (I) or a tautomer, stereoisomer, isotopologue, or salt thereof and a pharmaceutical composition containing same.

公开(公告)号：US20250136709A1

公开(公告)日：2025-05-01

申请号：US18944819

申请日：2024-11-12

Applicant: Development Center for Biotechnology

Inventor： Chun-Chung LEE ,  Yu-Hsun LO ,  Chu-Bin LIAO ,  Chen-Jei HONG ,  Sih-Yu CHEN ,  Yen-Yu WU ,  Szu-Liang LAI ,  Chih-Yung HU ,  Wen-Bin KE ,  Ya-Ting JUAN ,  Kao-Jean HUANG

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00

Abstract: The present invention relates to a novel antibody, an antigen-binding fragment thereof and the uses of the antibody and fragment, wherein the antibody and the fragment comprise specific complementarity-determining regions (CDRs) and/or specifically bind to human CD73 at specific epitopes.

公开(公告)号：US20230279139A1

公开(公告)日：2023-09-07

申请号：US17686666

申请日：2022-03-04

Applicant: Development Center for Biotechnology

Inventor： Chun-Chung LEE ,  Yu-Hsun LO ,  Chu-Bin LIAO ,  Chen-Jei HONG ,  Sih-Yu CHEN ,  Yen-Yu WU ,  Szu-Liang LAI ,  Chih-Yung HU ,  Wen-Bin KE ,  Ya-Ting JUAN ,  Kao-Jean HUANG

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00

CPC classification number: C07K16/2896 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/00 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/622 ,  A61K2039/505

Abstract: The present invention relates to a novel antibody, an antigen-binding fragment thereof and the uses of the antibody and fragment, wherein the antibody and the fragment comprise specific complementarity-determining regions (CDRs) and/or specifically bind to human CD73 at specific epitopes.

公开(公告)号：US20220289759A1

公开(公告)日：2022-09-15

申请号：US17636116

申请日：2020-08-22

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： Shao-Zheng PENG ,  Chu-Bin LIAO ,  Hung-Jyun HUANG ,  Yuan-Ting CHO ,  Yi-Mei CHANG ,  Yu-Chih PAN

IPC: C07D495/04 ,  C07D519/00 ,  A61P35/00

Abstract: A compound, which can act as inhibitors of protein kinases, especially Class III RTKs such as FLT3, PDGFRα, c-KIT and/or CSF-1R kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a binder of a Proteolysis-Targeting Chimera (PROTAC) thereof. The compound can be used in the treatments of diseases or conditions mediated by FLT3, PDGFR, c-KIT, and/or CSF-1R kinases, or mediated by a mutant kinase of FLT3, PDGFR, c-KIT, and/or CSF-1R kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.

公开(公告)号：US20220064310A1

公开(公告)日：2022-03-03

申请号：US17413496

申请日：2019-12-13

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： Chen-Hsuan HO ,  Chu-Bin LIAO ,  Yu-Kai CHEN ,  Chen-Wei HUANG ,  Tze-Ping YANG ,  Szu-Liang LAI

IPC: C07K16/28 ,  A61P35/00

Abstract: An antibody, or an antigen-binding fragment thereof, that binds specifically to human CSF-1R includes a heavy chain variable domain that contains a HCDR1 region having the sequence of SEQ ID NO: 4, a HCDR2 region having the sequence of SEQ ID NO: 5, and a HCDR3 region having the sequence of SEQ ID NO: 6; and a light chain variable domain that contains a LCDR1 region having the sequence of SEQ ID NO: 7, a LCDR2 region having the sequence of SEQ ID NO: 8, and a LCDR3 region having the sequence of SEQ ID NO: 9. The heavy chain variable domain comprises the sequence of SEQ ID NO: 2, and wherein the light chain variable domain comprises the sequence of SEQ ID NO: 3.